Kairos Pharma Reports Positive Phase 2 Data for Prostate Cancer Drug
Kairos Pharma announced positive interim efficacy data from its Phase 2 trial of ENV-105 in combination with apalutamide for metastatic prostate cancer.
Story updates
11:30:35 AM UTC
SquawkNews
Kairos Pharma reported that ENV-105 plus apalutamide showed median PFS of 17.7 months vs 2 months with apalutamide alone (P=0.0008) in an interim Phase 2 readout, and modified the trial to enroll earlier-stage patients using enzalutamide.Material DetailsContext by AI AnalystThis is an interim effic…